"A.M. Migliavacca" Center for Liver Disease, First Gastroenterology Unit, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Università di Milano, Via F. Sforza 35, 20122 Milan, Italy.
Viruses. 2009 Dec;1(3):484-509. doi: 10.3390/v1030484. Epub 2009 Oct 22.
One year of interferon therapy inhibits HBV replication in one third of the patients whereas long-term administration of oral nucleos(t)ide analogues is efficient in most of them, as long as early treatment adaptation in patients with partial virological response and resistance is provided. Following the demonstration of a more potent antiviral effect in terms of sustained virological response (SVR) rates, Pegylated-IFN coupled with Ribavirin has become the standard treatment for chronic hepatitis C, with nearly 65% of all treated patients achieving a SVR. Long-term suppression of HBV and eradication of HCV would halt the progression of chronic hepatitis to cirrhosis, hepatocellular carcinoma and liver decompensation.
一年的干扰素治疗可抑制三分之一患者的乙型肝炎病毒复制，而长期口服核苷（酸）类似物治疗在大多数患者中均有效，只要为部分病毒学应答和耐药的患者提供早期治疗调整。聚乙二醇干扰素联合利巴韦林在持续病毒学应答（SVR）率方面表现出更强的抗病毒效果后，已成为慢性丙型肝炎的标准治疗方法，所有接受治疗的患者中近 65%达到 SVR。长期抑制乙型肝炎病毒和清除丙型肝炎病毒可阻止慢性肝炎进展为肝硬化、肝细胞癌和肝功能失代偿。
